Kardigan, a San Francisco, CA-based heart health company modernizing cardiovascular drug development, raised USD300M in Series A funding.
The round was led by Perceptive Advisors, ARCH Venture Partners, and Sequoia Heritage.
The company intends to use the funds to advance its focus on areas of most unmet need in cardiology, starting with disease opportunities and patient segments that are resistant or poorly managed on current therapies, including primary and secondary cardiomyopathies leading to heart failure.
Led by CEO Tassos Gianakakos, CMO Jay Edelberg and CSO Bob McDowell, Kardigan is building a fully integrated biopharmaceutical company to advance treatments targeted to an individualās disease. Its R&D platform leverages a proprietary set of cardiac-specific tools that enable a deep understanding of the mechanisms across its therapeutic candidates as well as patientsā individualized responses to treatment. This approach matches critical disease drivers with treatment responders to streamline clinical trials and deliver novel therapies to those who have the greatest potential to benefit, while identifying alternative therapies for those who may not.
The broader executive team includes:
- Brianne Jahn, chief financial officer
- Minako Pazdera, Ph.D., J.D., general counsel and corporate secretary
- Emily Faucette, chief communications officer
- Diane Hagerty, chief quality officer
- Donald MacKenzie, Ph.D., chief technical operations officer
- Liz Nguyen, chief people officer
- Amy Westfall, vice president, portfolio and project management
FinSMEs
13/01/2025